The necessity for recognition and treatment of patients with 'mild' hypertension

Journal of the American College of Cardiology

Volumn 34, Issue 5, 1999, Pages 1369-1377

  Frohlich, Edward D ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; THIAZIDE DIURETIC AGENT; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BORDERLINE HYPERTENSION; CARDIOVASCULAR RISK; COMORBIDITY; DIURETIC THERAPY; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; LIFESTYLE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SYSTOLIC HYPERTENSION; TREATMENT INDICATION; TREATMENT PLANNING;

ANTIHYPERTENSIVE AGENTS; CORONARY DISEASE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; LIFE STYLE; MYOCARDIAL INFARCTION; RISK ASSESSMENT;

EID: 0033230060     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00361-7     Document Type: Review

References (97)

1. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure . The Sixth Report of the Joint National Committee (JNC-VI) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 157:1997;2413-2446.
2. Berlowitz D.R., Ash A.S., Hickey E.C., et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 339:1998;1957-1963.
3. Frohlich E.D. Defining borderline hypertension one remaining problem of preventive therapy in hypertension . Prev Cardiol. 4:1998;41-46.
4. National High Blood Pressure Education Program Working Group . National High Blood Pressure Education Program Working Group Report on Primary Prevention of Hypertension. Arch Intern Med. 153:1993;186-208.
5. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure . The Fifth Report of the Joint National Committee (JNC-V) on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 153:1993;154-183.
6. Burt V.L., Whelton P., Roccella E.J., et al. Prevalence of hypertension in the US adult population results from the Third National Health and Nutrition Examination Survey, 1988-1991 . Hypertension. 25:1995;305-313.
7. Reisin E., Frohlich E.D., Messerli F.H., et al. Cardiovascular changes after weight reduction in obesity hypertension. Ann Intern Med. 98:1983;315-319.
8. Expert Panel on the Identification and Treatment of Overweight and Obesity in Adults . Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Int Med. 158:1998;1855-1867.
9. Frohlich E.D., Gifford R. Jr, Horan M., et al. Nonpharmacologic approaches to the control of high blood pressure. Report of the Subcommittee on Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 8:1986;444-467.
10. Frohlich E.D. Obesity-hypertension. Converting enzyme inhibitors and calcium antagonists. Hypertension. 19:1992;119-123.
11. Frohlich E.D. Nonpharmacological approaches to treatment of hypertension in the elderly. Am J Geriatr Cardiol. 5:1996;50-56.
12. Boushey C.G., Beresford S.A.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease probable benefits of increase in folic acid intakes . JAMA. 274:1995;1049-1057.
13. Morrison H.I., Schaubel D., Desmules M., Wigle D.T. Serum folate and risk of fatal coronary disease. JAMA. 375:1996;1893-1896.
14. Brand F.H., McGee D.L., Kannel W.B., Stokes J., Castelli W.P. Hyperuricemia as a risk factor of coronary heart disease The Framingham Study . Am J Epidemiol. 12:1985;8-11.
15. Frohlich E.D. Uric acid - a risk factor for coronary heart disease. JAMA. 270:1993;378-379.
16. Stanton J.R., Freis E.D. Serum uric acid concentration in essential hypertension. Proc Soc Exper Biol Med. 66:1947;193-194.
17. Messerli F.H., Frohlich E.D., Dreslinski G.R., Suarez D.H., Aristimuño G.G. Serum uric acid in essential hypertension an indicator of renal vascular involvement . Ann Intern Med. 93:1980;817-821.
18. Nunez B.D., Frohlich E.D., Garavaglia G.E., Schmieder R.E., Nunez M.M. Serum uric acid in renovascular hypertension reduction following surgical correction . Am J Med Sci. 294:1987;419-422.
19. Kobrin I., Frohlich Ed, Ventura H.O., Messerli F.H. Renal involvement follows cardiac enlargement in essential hypertension. Arch Intern Med. 146:1986;272-276.
20. Frohlich E.D., Apstein C., Chobanian A.V., et al. The heart in hypertension. N Engl J Med. 327:1992;998-1008.
21. Frohlich E.D. Current clinical pathophysiologic considerations in essential hypertension. Med Clin North Am. 81:1997;1113-1129.
22. Frohlich E.D. Hypertension left ventricular hypertrophy, and coronary flow reserve. Zanchetti A., Devereux R.B., Hansson L., Gorini S., Hypertension and the Heart. 1997;253-262 Plenum, New York.
23. Frohlich E.D., Re R.N. Pathophysiology of systemic arterial hypertension. Alexander R.W., Schlant R.C., Fuster V., O'Rourke R.A., Roberts R., Sonnenblick E.H., Hurst's The Heart. Ninth ed. 1998;1635-1650 McGraw-Hill, New York.
24. Medical Research Council Working Party . MRC trial of treatment of mild hypertension principal results . Br Med J. 291:1985;97-104.
25. Management Committee of the Australian National Blood Pressure Study . The Australian therapeutic trial in mild hypertension. Lancet. 1:1980;1261-1267.
26. Whelton P.K., He J., Cutler J.A., et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA. 277:1977;1624-1632.
27. Kawano Y., Matsuoka H., Takashita S., Omae T. Effects of magnesium supplementation in hypertensive patients. Assessment by office, home, and ambulatory home blood pressures. Hypertension. 32:1998;360-365.
28. He J, Whelton PK. Epidemiology and prevention of hypertension. In: Frohlich ED, editor. Essential Hypertension Part I. Med Clin North Am 1997;81:1077-97.
29. Messerli F.H., Grossman E., Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? JAMA. 279:1998;1903-1907.
30. MRC Working Party . Medical Research Council trial of treatment of hypertension in older adults principal results . Br Med J. 304:1992;405-412.
31. Veterans Administration Cooperative Study Group in Antihypertensive Agents . Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. I. Results of short-term titration with emphasis on renal differences in response. JAMA. 248:1982;1996-2003.
32. Freis ED. Current status of diuretics, β-blockers, α-blockers, and α-β-blockers in the treatment of hypertension. In: Frohlich ED, editor. Essential Hypertension. Part II. Med Clin North Am 1997;80:1305-17.
33. VHAS Investigators , Rosei E.A., Dal Palu C., Leonetti G., et al. Clinical results of the verapamil in hypertension and atherosclerosis study. J Hypertens. 15:1997;1337-1344.
34. Verapamil in Hypertension and Atherosclerosis Study (VHAS) Investigators , Zanchetti A., Rosei E.A., Dal Palu C., et al. The verapamil in hypertension and atherosclerosis study (VHAS) results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness . J Hypertens. 16:1998;1967-1976.
35. Collins C., Peto R., MacMahon S., et al. Blood pressure, stroke and coronary heart disease. Part II. Short-term reductions in blood pressure overview of randomized drug trials in their epidemiological context. Lancet. 335:1990;827-838.
36. Nunez E., Hosoya H., Susic D., Frohlich E.D. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension. 29:1997;519-524.
37. Susic D., Nunez E., Hosoya H., Frohlich E.D. Coronary hemodynamics in aging spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY) rats. J Hypertens. 16:1998;231-237.
38. Marcus M.L., Doty D.B., Hiratzka L.F., Wright C.B., Eastham C.L. Decreased coronary reserve a mechanism for angina pectoris in patients with aortic stenosis and normal coronary arteries . N Engl J Med. 307:1982;1362-1367.
39. Opherk D., Mall G., Zebbe H., et al. Reduction of coronary reserve a mechanism for angina pectoris in patients with arterial hypertension and normal coronaries . Circulation. 69:1984;1-7.
40. Brush J.E., Cannon R.O., Schenke W.H., et al. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med. 319:1988;1302-1307.
41. Houghton J.L., Frank M.J., Carr A.A., et al. Relations among impaired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without destructive coronary artery disease. J Am Coll Cardiol. 15:1990;43-51.
42. Scheler S., Wolfgang M., Strauer B.E. Mechanisms of angina pectoris in patients with systemic hypertension and normal epicardial arteries by arteriogram. Am J Cardiol. 73:1994;478-482.
43. Treasure C.B., Klein J.C., Vita J.A., et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary artery resistance vessels. Circulation. 87:1993;86-93.
44. Brutsaert D.L., Fransen P., Andries L.J., De Keulenaer G.W., Sys S.U. Cardiac endothelium and myocardial function. Cardiovas Res. 38:1998;281-290.
45. Multiple Risk Factor Intervention Trial Research Group . Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial findings to a prior hypothesis of the trial . JAMA. 263:1990;1795-1801.
46. Siscovick D.S., Raghunathan T.E., Psaty B.M., et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 330:1994;1852-1857.
47. SHEP Cooperative Research Group , Savage P.J., Pressel S.L., Curb J.D., et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Arch Intern Med. 158:1998;741-751.
48. Thijs L., Fagard R., Lijuen F., et al. A meta-analysis of outcome trials in elderly hypertensives. J Hypertens. 10:1992;1103-1109.
49. β-Blocker Heart Attack Study Group . The β-Blocker Heart Attack Trial. JAMA. 246:1981;2073-2074.
50. Norwegian Multicenter Study Group . Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 304:1981;801-807.
51. Hjalmarson A., Elmfeldt D., Herlitz J. Effect on mortality of metroprolol in acute myocardial infarction a double-blind randomized trial . Lancet. 2:1981;823-827.
52. Motz W., Strauer B.E. Improvement of coronary flow reserve after long-term therapy with enalapril. Hypertension. 27:1996;1031-1038.
53. Frohlich E.D., Arthur C. Corcoran Memorial Lecture influence of nitric oxide and angiotensin II on renal involvement in hypertension . Hypertension. 29:1997;188-193.
54. Vaughan D.E. Plasminogen activator inhibitor-1 a common denominator in cardiovascular disease . J Invest Med. 46:1998;370-376.
55. Givertz M.M., Colucci W.S. New targets for heart-failure therapy endothelin, inflammatory cytokines, and oxidative stress . Lancet. 352:(Suppl 1):1998;34-38.
56. SAVE Investigators , Pfeffer M.A., Braunwald E., Moyé L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 327:1992;669-677.
57. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators . Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;821-828.
58. Yusuf S., Pepine C.J., Garces C., et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 340:1992;1173-1178.
59. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 339:1998;489-497.
60. Topol E.J., Traill T.A., Fortuin N.J. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med. 312:1985;277-283.
61. Janicki J.S., Matsubara B.B. Myocardial collagen and left ventricular diastolic dysfunction. Gasch W.H., LeWinter M.M., Ventricular Diastolic Dysfunction. 1993;125-140 Lea & Febiger, Philadelphia.
62. Susic D., Francischetti A., Frohlich E.D. Prolonged L-arginine on cardiovascular mass and myocardial hemodynamics and collagen in aged spontaneously hypertensive rats and normal rats. Hypertension. 33:1999;451-455.
63. Brilla C.G., Matsubara L., Weber K.T. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension. 28:1996;269-275.
64. Rossi M.A. Pathologic fibrosis and connective tissue maxtrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens. 16:1998;1031-1041.
65. Packer M. Do angiotensin converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol. 28:1996;1323-1327.
66. Cruickshank J.M., Thorpe J.M., Zacharias F.J. Benefits and potential harm or lowering high blood pressure. Lancet. 1:1987;581-584.
67. Alderman M.H., Ooi W.L., Madharan S. Treatment induced blood pressure reduction and the risk of myocardial infarction. JAMA. 262:1989;920-924.
68. Farnett L., Mathew C.D., Linn W.D., et al. The J-curve phenomenon on the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA. 265:1991;489-495.
69. SHEP Cooperative Research Group . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 265:1991;3255-3264.
70. Dahlöf B., Lindholm L.H., Hansson L., Schersten B., Eckbom T., Wester P.O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 338:1991;1281-1285.
71. Systolic Hypertension - European (Syst-Eur) Trial Investigators , Staessen J.A., Faggard R., Thijs L., et al. Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet. 1997;360-764.
72. Hot Study Group , Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension principal results of the hypertension optimal treatment (HOT) randomized trial . Lancet. 351:1998;1733-1762.
73. Klahr S., Levey A.S., Beck G.J., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 330:1994;877-884.
74. Maschio G., Alberti D., Janin G., et al. Effect of the angiotensin-converting-enzyme inhibitor benazapril on the progression of chronic renal insufficiency. N Engl J Med. 334:1996;939-945.
75. Modification of Diet in Renal Disease Study Group , Lazarus J.M., Bourgoinie J.J., Buckalew V.M., et al. Achievement and safety of a low blood pressure goal in chronic renal disease. Hypertension. 29:1997;641-650.
76. Modification of Diet in Renal Disease Study Group , Hebert L.E., Kusek J.W., Greene T., et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Hypertension. 30:1997;428-435.
77. U.K. Prospective Diabetes Study Group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 38 . Br Med J. 317:1998;703-713.
78. U.S. Renal Data Systems . 1995 Annual Data Report National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases. III. Incidence and causes of treated ESRD . Am J Kidney Dis. 26:1995;539-550.
79. Ono Y., Ono H., Frohlich E.D. Hydrochlorothiazide exacerbates nitric oxide-blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens. 14:1996;823-828.
80. Brenner B.M., Mayer T.W., Hostetter T.H. Dietary protein intake and the progressive nature of kidney disease the role of hemodynamically radiated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease . N Engl J Med. 307:1982;652-659.
81. Lewis E.J., Hunsicker L.G., Bain B.P., et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 329:1993;1456-1462.
82. GISEN Group (Gruppo Italiano Di Studi Epidemiologic Di Nephrologia) . Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuria, non-diabetic nephropathy. Lancet. 349:1997;1857-1863.
83. Cooper M.E. Renal protection and angiotensin converting enzyme inhibition in microalbumin uric type I and type II diabetic patients. J Hypertens. 14:1996;S11-S14.
84. MacLeod M.J., McLay J. Drug treatment of hypertension complicating diabetes mellitus. Drugs. 56:1998;189-202.
85. Bakris G.L., Copley J.B., Vicknair N., et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy results of a six year study . Kidney Int. 50:1996;1641-1650.
86. Angiotensin-Converting Enzyme Inhibition, Progressive Renal Disease Study Group , Giatras J., Lau J., Levey A.S. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease a meta-analysis of randomized trials . Ann Intern Med. 127:1997;337-345.
87. Zucchelli P., Zuccala A. Progression of renal failure and hypertensive nephrosclerosis. Kidney Int. 54:(Suppl 68):1998;55-59.
88. Gonzalez-Albarran O., Garcia Robles R., Ruilop L.M. Therapeutic implications and new perspectives for essential hypertension and renal damage. Kidney Int. 54:(Suppl 68):1998;S46-S50.
89. Hall D.W., Reed J.W., Flack J.M., et al. Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. Arch Intern Med. 158:1998;2029-2034.
90. AASK Pilot Study Investigators , Fogo A., Breyer J.A., Smith M.C., et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans a report from the African American Study of Kidney Disease (AASK) trial . Kidney Int. 51:1997;244-252.
91. Amodeo C., Ventura H.O., Messerli F.H., Frohlich E.D. Immediate and short-term hemodynamic effects of diltiazem in patients with hypertension. Circulation. 73:1986;108-113.
92. Isshiki T., Amodeo C., Messerli F.H., Pegram B.L., Frohlich E.D. Diltiazem maintains vasodilation without hyperfiltration in hypertension studies in essential hypertensive man and the spontaneously hypertensive rat . Cardiovasc Drugs Ther. 1:1987;359-366.
93. Grossman E., Oren S., Garavaglia G.E., Messerli F.H., Frohlich E.D. Systemic and regional hemodynamic and humoral effects of nitrendipine in essential hypertension. Circulation. 78:1988;1395-1400.
94. Franscischetti A., Ono H., Frohlich E.D. Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension. 31:1998;795-801.
95. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., Schrier R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with noninsulin-dependent diabetes and hypertension. N Engl J Med. 333:1998;645-652.
96. McKee P.A., Castelli W.P., McNamara P.M., Kannel W.B. The natural history of congestive heart failure the Framingham Heart Study . N Engl J Med. 285:1971;1441-1446.
97. Vasan R.S., Levy D. The role of hypertension in pathogenesis of heart failure a clinical mechanistic overview . Arch Intern Med. 156:1996;1789-1796.